Radioactive antibody targets Hard-to-Treat cancers in early trial

NCT ID NCT06824155

First seen Feb 15, 2026 · Last updated May 15, 2026 · Updated 17 times

Summary

This early-phase study tests a new drug called 177Lu-RAD202, which is a radioactive antibody that seeks out and attaches to HER2 proteins on cancer cells. The goal is to see if it is safe and to find the right dose for people with advanced solid tumors that have not responded to other treatments. About 30 adults with HER2-positive or HER2-low cancers will take part, first receiving a small imaging dose to see where the drug goes, then a treatment dose to attack the tumors.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • GenesisCare Murdoch

    RECRUITING

    Murdoch, Western Australia, 6150, Australia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Macquarie University Hospital

    RECRUITING

    Macquarie Park, New South Wales, 2109, Australia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Nepean Hospital

    RECRUITING

    Kingswood, New South Wales, 2747, Australia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • St Vincents Hospital, Melbourne

    NOT_YET_RECRUITING

    Fitzroy, Victoria, 3065, Australia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Wollongong Hospital

    RECRUITING

    Wollongong, New South Wales, 2500, Australia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.